EN | English
Skyhawk’s RNA splicing modulators can address a broad range of diseases.
Our wholly-owned pipeline includes programs across neurodegenerative, neuromuscular, oncology, fibrotic and other disease types. Many of our programs address targets formerly considered “undruggable” using traditional protein-targeting mechanisms.
RNA mis-expression is central to a host of diseases. Very few treatments are available for these challenging conditions, many of which have been considered "undruggable".
Skyhawk’s potent small molecule drug candidates target RNA across a broad range of diseases, from orphan and neurological conditions to major cancers.
